Answers are grounded in this paper and cite their sources.
Significance PARP is an important target in the treatment of cancers, particularly in patients with breast, ovarian, or prostate cancer that have compromised homologous recombination repair (i.e., BRCA −/− ). This review about inhibitors of PARP (PARPi) is for readers interested in the development of next-generation drugs for the treatment of cancer, providing insights into structure–activity relationships, in vitro vs. in vivo potency, PARP trapping, and synthetic lethality.
No takes yet. Share an insight, caveat, or question.
Rudolph et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: